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EDITORIAL
Trials and Tribulations in Studying Kidney Outcomes With Intentional Weight Loss
Article, see p 366 E xperimental studies and epidemiological investigations have implicated obesity as a risk factor for the development of kidney disease, 1,2 even in the absence of diabetes mellitus and hypertension. Several mechanisms, including glomerular hyperfiltration (the kidneys' ability to compensate for the higher body mass index) and altered adipokine profile such as low adiponectin level, contribute to the onset of kidney disease. Kidney conditions linked to obesity are not just limited to incident chronic kidney disease (CKD), defined as estimated glomerular filtration rate (eGFR) <60 mL·min -1 ·1.73 m -2 , but also include kidney cancer and kidney stones. 3 It is conceivable that intentional weight loss using lifestyle modifications and medications among those with preserved kidney function or mild to moderate CKD could slow down the progression of kidney disease and improve cardiovascular outcomes. Lifestyle modification is a core component for achieving weight loss, but adherence and weight regain are major barriers to its longterm success. Medications are increasingly used as an adjunct to treat obesity, and various agents have become available in recent years. Undesirable cardiovascular effects have led to the withdrawal of medications to treat obesity (sibutramine). Newer agents such as lorcaserin, an agent that binds to 5-HT2C receptors in the hypothalamic pro-opiomelanocortin pathway and promotes satiety, has been reported to help patients lose weight successfully. 4 In the current issue of Circulation, Scirica et al 5 report a prespecified secondary analysis of a multinational, randomized placebo-controlled trial that examined the effects of lorcaserin on various kidney parameters. Investigators enrolled 12 000 overweight or obese patients (body mass index >27 kg/m 2 ) with pre-existing cardiovascular disease or multiple cardiovascular risk factors. The presence of dyslipidemia, hypertension, eGFR 30 to 60 mL·min -1 ·1.73 m -2 , high-sensitivity C-reactive protein >3 mg/L, or the presence of micro-or macroalbuminuria was considered a cardiovascular risk factor for inclusion in the trial. Those with advanced kidney disease (eGFR <30 mL·min -1 ·1.73 m -2 ) and end-stage kidney disease were excluded. Participants received lorcaserin 10 mg twice daily or placebo along with an opportunity to participate in a standardized weight management program that included dietary and exercise information and access to a registered dietitian. In previous publications, investigators reported that lorcaserin facilitates sustained weight loss without a higher rate of major cardiovascular events (including cardiac valvulopathy) and decreases the risk of incident diabetes mellitus and induces remission of hyperglycemia. 6, 7 Herein, authors studied the effects of lorcaserin on a composite kidney outcome: new or worsening micro-or macroalbuminuria, new or worsening CKD, doubling of serum creatinine, end-stage kidney disease, renal transplant, and renal death.
At the onset of the trial, median eGFR was 76 mL·min -1 ·1.73 m -2 (interquartile range, 63-89), and urinary albumin:creatinine ratio (UACR) was 7.0 mg/g (interquartile range, 3.9, 20) with 19.6% of patients having an eGFR <60 mL·min -1 ·1.73 m -2 and 19.0% of them with albuminuria (UACR ≥30 mg/g). In the lorcaserin group, mean weight loss was 2 to 3 kg higher and hemoglobin A1c was 0.2% lower along with 1 mm Hg lower systolic blood pressure than the placebo group. In the treatment group, eGFR during follow-up was 0.9, 1.3, and 1.8 mL·min -1 ·1.73 m -2 higher in those with baseline eGFR >90, 60 to 90, and <60 mL·min -1 ·1.73 m -2 , respectively. UACR was 9 mg/g and 7 mg/g lower in the treatment group than in the placebo group at 1-and 3-year follow-up. Lorcaserin reduced the risk of the primary renal composite outcome by 13% (hazard ratio, 0.87; 95% CI, 0.79-0.96); it is notable that the impact of lorcaserin was significant only for 2 components of the composite measure: persistent new or worsening albuminuria (hazard ratio, 0.86; 95% CI, 0.76-0.97) and new or worsening CKD stage (hazard ratio, 0.81; 95% CI, 0.72-0.93), surrogate end points of kidney disease progression. Improvements in eGFR and UACR were evident in year 1 and sustained throughout the study period of >3 years. Adverse events such as rhabdomyolysis and acute kidney injury did not differ between the groups. Finally, similar to data from other population-based studies, lower levels of kidney function (low eGFR and high UACR) were associated with a higher risk of major atherosclerotic cardiovascular events in the entire study population.
A significant strength of this report includes being a prespecified secondary analysis of a large clinical trial with 3-year follow-up. Changes in eGFR and UACR (measured in a central laboratory) during follow-up were confirmed with a subsequent measurement, strengthening our confidence. However, several limitations have to be considered while interpreting these results. Despite being statistically significant, observed eGFR and UACR changes (as continuous variables) with treatment were small, with the number needed to treat for composite outcome 1 in 142. Both fat and lean body mass decrease with weight loss, and reduction in muscle mass could lead to lower serum creatinine levels and, thus, higher eGFR. 8 These effects are more pronounced with surgical weight loss than the modest weight loss achieved with lifestyle modifications and medications. eGFR improved and UACR decreased in the first year of the study; whether these benefits are attributed to the direct effects of weight loss on the kidney (by ameliorating glomerular hyperfiltration and altering adipokine profile) or to the impact of the drug per se merits further studies. Because the effects on hemoglobin A1c and blood pressure were marginal with the intervention, metabolic improvements are unlikely to solely explain the noted benefits. The CKD-EPI equation (Chronic Kidney Disease Epidemiology Collaboration) was used to calculate eGFR, which is subject to less bias (in comparison with the MDRD equation [Modification of Diet in Renal Disease Study]), especially in those with eGFR >60 mL·min -1 ·1.73 m -2 and who are obese. 9 But the validity of the CKD-EPI equation among morbidly obese (body mass index >40 kg/m 2 ) is still uncertain. It is noteworthy that the superiority of the CKD-EPI and MDRD equations among those undergoing weight loss wherein the body surface area is changing has not been established. Both of these estimating equations adjust for a body surface area of 1.73 m 2 , which might not be appropriate in those who are morbidly obese, and the influence of the change in body weight on body surface area is unknown. 10 These data are encouraging; however, future studies addressing some unanswered questions would strengthen the evidence base for the kidney benefits of lorcaserin. Lorcaserin undergoes hepatic metabolism and is excreted in the urine. Exposure to lorcaserin metabolite is higher among those with lower creatinine clearance, and whether the adverse event rates differ based on kidney function warrant further investigations. Studies comparing measured GFR (using inulinclearance, chromium-EDTA, or iohexol clearance) with creatinine-based eGFR in weight loss studies is vital, and an alternate option is to use the cystatin C-based equation because it is less influenced by muscle mass and dietary intake. Is there a correlation between the degree of weight loss achieved and progression of kidney disease, ie, is there a dose-dependent effect? It is important, because only 38% of patients taking lorcaserin lost >5% of body weight, and it is anticipated that patients have to be continued on these agents to sustain weight loss, pointing out the need for studies focusing on long-term efficacy and safety.
In the context of these data, what can clinicians recommend to those with obesity and mild to moderate kidney disease who constitute the majority of the CKD population? For those with preserved kidney function, results of this analysis provide data on an additional health benefit to pursue weight loss. This report also included ≈20% of patients with eGFR <60 mL·min -1 ·1.73 m -2 for whom the options for intentional weight loss are limited. Dietary options that often contain very high protein diets might not be ideal for those with pre-existing kidney disease. Physical inactivity is common among those who are obese, and >50% of those with eGFR <60 mL·min -1 ·1.73 m -2 do not adhere to the recommended physical activity levels. 11 However, secondary analysis of the LookAHEAD study (Action for Health in Diabetes) (which compared intensive lifestyle modification versus diabetes support and education for those with obesity and type 2 diabetes mellitus) reported improvement in the risk of CKD with intensive lifestyle modification. 12 Therefore, motivating patients to increase their physical activity and adhere to lifestyle modification is the first and essential step. Patients with advanced kidney disease often lose weight as the disease progresses (unintentionally), which is often difficult to differentiate from intentional weight loss; hence, close monitoring of these patients is critical. 13 In the US general population, of individuals who were overweight or obese and attempted to lose weight, 16% of the non-CKD population and 8% of patients with CKD reported taking weight loss medications. 11 Studies comparing different weight loss medications are limited in the general population, and a comparison of them with placebo is lacking in those with pre-existing kidney disease. Observational data report that orlistat use was associated with higher risk of acute kidney injury, 14 and whether the use of these agents in those with CKD would hasten kidney disease progression is of concern. Recent data suggest the weight loss potential of glucagon-like peptide-1 agonists that could be used in patients with diabetes mellitus and kidney disease. Along with its hypoglycemic effects, liraglutide use is associated with higher odds of achieving >5% weight loss. However, secondary analysis of a large controlled trial comparing liraglutide with placebo reported benefits with improvement in albuminuria but not eGFR. 15 Unfortunately, the available evidence is not robust enough to routinely recommend medications to facilitate weight loss in those with obesity and CKD (Table) . Surgical weight loss offers sustained metabolic benefits, with observational data suggesting renal benefits that are yet to be confirmed in clinical trials.
In summary, although the report by Scirica et al 5 suggests potential benefits of lorcaserin for surrogate kidney outcome measures, these benefits are marginal. Additional studies examining the impact of lorcaserin on end points such as endstage kidney disease and the adverse event profile based on kidney function, are needed. 
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